Simultaneous Single-Cell DNA and Protein Sequencing in AML Samples
This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases.
Genomic studies of AML have identified mutations with varying allele frequencies, which suggests a step-wise acquisition of mutation in leukemogenesis. Bulk sequencing can provide prognostic information, but it cannot delineate clonal architecture at the single-cell level. Additionally, the complementation of immunophenotype with corresponding mutational analysis could elucidate important dynamics in the leukemic cell population, but has yet to be assayed in parallel.
In this webinar, Linde Miles of Memorial Sloan Kettering Cancer Center will share data from the study demonstrating that simultaneous single-cell sequencing of DNA and protein can identify populations of stem/progenitor cells with distinct clonal/mutational and protein expression profiles. She will also discuss how the method identified trends in protein expression when comparing multiple samples with similar mutations.
Attendees of this webinar will learn about:
- New DNA+protein capability from Mission Bio for simultaneous, targeted, single-cell DNA and protein sequencing
- A novel 6-antibody cocktail in combination with a single-cell targeted DNA custom AML panel
- The relationship between mutational profile and cell surface protein expression in AML samples from six clinical research samples
Linde A. Miles, PhD
Postdoctoral Research Fellow,
Memorial Sloan Kettering Cancer Center